Clinical trials: Refractory Rheumatoid Arthritis (RA)
Rheumatoid Arthritis
Phase 2b Study of MBS2320 in Participants With Methotrexate-Refractory RA
Rheumatoid arthritis (RA) affects 1 percent of the population worldwide and up to 40 percent of patients don't respond to current treatments.
- Trial name
- NCT05460832
- Testing
- MBS2320 5 mg, MBS2320 20 mg, MBS2320 40 mg
- Where
- 46 sites in Bosnia and Herzegovina, Bulgaria and 6 more
- Volunteers
- 248 people
- Sponsor
- Modern Biosciences Ltd
Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc)
A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), etc.
- Conditions
- Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), Inflammatory Myopathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Trial name
- NCT06978647
- Testing
- YTS109 cell
- Where
- China
- Volunteers
- 12 people
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.
Rheumatoid Arthritis (RA)
Masitinib in Refractory Active Rheumatoid Arthritis
The objective is to compare efficacy and safety of masitinib at 3 and 6 mg/kg/day to methotrexate, with a randomisation 1:1:1, in treatment of patients with active rheumatoid arthritis with inadequate response to 1.
- Trial name
- NCT01410695
- Testing
- masitinib 3 mg, masitinib 6.0 mg, methotrexate
- Where
- Czechia
- Volunteers
- 324 people
- Sponsor
- AB Science
Rheumatoid Arthritis (RA)
Telitacicept for the Treatment of Refractory RA
This is a single-center, single-arm, open-label, prospective study on the efficacy and safety of Telitacicept in patients with refractory rheumatoid arthritis.
- Trial name
- NCT07008196
- Testing
- Telitacicept
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese SLE Treatment And Research Group
Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM)
Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
A Phase 1 study of HBI0101 BCMA-CART in B-Cell Mediated Autoimmune Rheumatic Diseases. The goal of the study is evaluation of safety and identification of the maximum HBI0101 CART dose that may be administered safely to patients…
- Conditions
- Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM), Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
- Trial name
- NCT07085676
- Testing
- HBI0101 CART
- Where
- Israel
- Volunteers
- 120 people
- Sponsor
- Polina Stepensky
Rheumatoid Arthritis (RA)
The Clinical Study on the Treatment of Refractory RA With UTAA91 Injection
This clinical trial is designed as a single - arm, open - label, single - center, investigator - initiated early - phase clinical study.
- Trial name
- NCT07001956
- Testing
- UTAA91 injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic Autoimmune Rheumatic Diseases
This is an open-label, single-dose, prospective, monocenter, Phase I interventional study (not first-in-human) to assess the safety, tolerability, and preliminary efficacy of autologous anti-CD19 CAR-T cells as an advanced…
- Conditions
- Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Sjogren's Disease With Dry Eyes, Systemic Sclerosis (SSc)
- Trial name
- CELL-ATTACK 1 (NCT07544225)
- Testing
- anti-CD19 CAR-T cells
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs)
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of AlloNK, a non-genetically…
- Conditions
- Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA
- Trial name
- NCT06991114
- Testing
- Allogeneic NK Cells
- Where
- 52 sites in United States, Brazil and 9 more
- Volunteers
- 90 people
- Sponsor
- Artiva Biotherapeutics, Inc.
Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus (SLE)
BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease
Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory autoimmune disease, however not all disease responds or remains in response to CD19 targeted CAR-T cells.
- Conditions
- Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus (SLE), Dermatomyositis (DM), Systemic Sclerosis (SSc)
- Trial name
- NCT07729995
- Testing
- LMY-922
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Luminary Therapeutics
Rheumatoid Arthritis
Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis
The RESET-RA study will assess the safety and efficacy of the SetPoint System (study device) for the treatment of adult patients with active, moderate to severe rheumatoid arthritis who have had an inadequate response or…
- Trial name
- RESET-RA (NCT04539964)
- Testing
- Implant Procedure, Conventional Synthetic DMARD, Active stimulation
- Where
- 42 sites in United States
- Volunteers
- 243 people
- Sponsor
- SetPoint Medical Corporation
Refractory Autoimmune Diseases
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
The purpose of this study is to determine the safety, tolerability, optimal dose, and preliminary efficacy of BMS-986515, a healthy donor (HD) allogeneic CD19-targeted CART cell product, in participants with severe, refractory…
- Trial name
- NCT07115745
- Testing
- BMS-986515, Fludarabine, Cyclophosphamide
- Where
- 28 sites in United States, Australia and 8 more
- Volunteers
- 125 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Rheumatoid Arthritis (RA)
Integrated Clinical Study of Traditional Chinese and Western Medicine for Refractory Rheumatoid Arthritis
To evaluate the efficacy and safety of Kunxian Capsule combined with Methotrexate and Tofacitinib in the treatment of difficult-to-treat rheumatoid arthritis through a multicenter, randomized, double-blind, placebo-controlled…
- Trial name
- NCT07721142
- Testing
- Kunxian Capsule
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine
Rheumatoid Arthritis (RA)
An Open-label Study of Cizutamig in Refractory Seropositive Rheumatoid Arthritis
The purpose of the study is to evaluate the safety and efficacy of BCMAxCD3 T-cell engager (cizutamig) in patients with refractory seropositive RA.
- Trial name
- NCT06946199
- Testing
- Cizutamig
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Arthritis, Rheumatoid
A Long-term Safety Extension Study of Tocilizumab in Brazilian Participants With Rheumatoid Arthritis (RA) Who Completed the Studies ML21530 and MA21488
This multicenter, open-label, single-arm extension study will evaluate the long-term safety of tocilizumab (RoActemra/Actemra) in participants with RA.
- Trial name
- RITACT (NCT01715831)
- Testing
- DMARDs, Tocilizumab
- Where
- 9 sites in Brazil
- Volunteers
- 26 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis (RA
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis
A Phase I, open-label study of CLN-978 in patients with treatment-refractory rheumatoid arthritis.
- Trial name
- NCT06994143
- Testing
- CLN-978
- Where
- 4 sites in Germany, Italy
- Volunteers
- 37 people
- Sponsor
- Cullinan Therapeutics Inc.
Telitacicept, Treatment Compliance
Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis
The aim of this study is to observe the clinical efficacy and safety of telitacicept combined with baricitinib in the treatment of D2TRA patients
- Conditions
- Telitacicept, Treatment Compliance, Rheumatoid Arthritis
- Trial name
- NCT07491016
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Provincial People's Hospital
Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM)
Safety Study of CC312 in Autoimmune Disease Patients
This study is an open-label, multiple-dose escalation, Investigator-Initiated Trial (IIT) clinical trial designed to evaluate the safety and tolerability of CC312 in adult patients with relapsed and refractory autoimmune…
- Conditions
- Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA)
- Trial name
- NCT06888960
- Testing
- CC312
- Where
- China
- Volunteers
- 18 people
- Sponsor
- CytoCares Inc
Rheumatoid Arthritis
GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy
The purpose of this study is to determine the PK/PD, efficacy and safety of GP2013 in patients with severe rheumatoid arthritis.
- Trial name
- NCT01274182
- Testing
- GP2013, MabThera, Rituxan
- Where
- 57 sites in United States, Argentina and 12 more
- Volunteers
- 312 people
- Sponsor
- Sandoz
Rheumatoid Arthritis (RA)
At-home Ultrasound Localized Therapy for Rheumatoid Arthritis Study [At-home ULTRA Study]
The At-Home ULTRA Study will evaluate performance of the MINI system as indicated for the treatment of adults with active, moderate to severe rheumatoid arthritis who are inadequate responders or are intolerant to conventional…
- Trial name
- At-home ULTRA (NCT07163221)
- Testing
- Non-invasive ultrasound stimulation of the spleen - Treatment Setting 1, Non-invasive ultrasound stimulation of the spleen - Treatment Setting 2, Conventional Synthetic DMARD
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- SecondWave Systems Inc.
Rheumatoid Arthritis Aggravated
Cx611-0101, eASCs Intravenous Administration to Refractory Rheumatoid Arthritis Patients
Phase Ib/IIa clinical trial of a new medicinal product of the somatic cell therapy class (eASCs). This study is designed as a multicenter, single blind, fixed dose escalation, with three treatment groups, controlled with placebo…
- Trial name
- NCT01663116
- Testing
- Stem cells
- Where
- 23 sites in Spain
- Volunteers
- 53 people
- Sponsor
- Tigenix S.A.U.